Opinion

Video

Overview of the CAPItello-291 Trial

Author(s):

Joyce O’Shaughnessy, MD,Laura Huppert, MD

Panelists discuss the findings of the CAPItello-291 trial, which investigated capivasertib combined with fulvestrant in advanced hormone receptor–positive, HER2-negative breast cancer, leading to its approval in November 2023 and highlighting its potential as a new targeted therapy option in the second-line setting due to the prevalence of PIK3CA, AKT1, and PTEN alterations.

Video content above is prompted by the following:

  1. Dr Huppert: Please summarize the findings of the CAPItello-291 trial investigating capivasertib plus fulvestrant in the advanced hormone receptor–positive, HER2- negative setting, which led to its approval in November 2023. Turner NEJM 2023
  2. Given the frequency of P13KCA, AKT1, and PTEN alterations, how does capivasertib plus fulvestrant represent a new targeted therapy option in the second-line setting?
  3. Dr Huppert: What patient factors do you consider when initiating patients on capivasertib?

Related Content